**Core tip:** Elastography point quantification (ElastPQ) is a non-invasive technique for assessing tissue stiffness, and was used in this study. Splenectomy is a surgical intervention for liver cirrhosis patients with hypersplenism. The aim of the current study was to evaluate the diagnostic accuracy of liver stiffness measurement by ElastPQ in animal models and determine the longitudinal changes in liver stiffness by ElastPQ after splenectomy at different stages of fibrosis. We conclude that liver stiffness measurements using ElastPQ can be used to dynamically monitor the changes in liver stiffness in rabbit models, and in patients, after splenectomy.

INTRODUCTION
============

Liver fibrosis, which is characterized by encapsulation or replacement of injured tissue by a collagenous scar\[[@B1]\], represents a common pathological process in chronic liver injury of varying etiologies. Cirrhosis, which is morphologically described as abnormal liver architecture encompassing fibrous bands surrounding regenerative nodules, is the end stage of liver fibrosis and has clinical complications, including liver failure, portal hypertension, and ultimately, hepatocellular carcinoma. A growing body of clinical evidence has indicated that liver fibrosis can reverse and possibly return to normal following the development of effective treatments for chronic hepatitis infection (B and C)\[[@B2]-[@B6]\], autoimmune hepatitis\[[@B7]\], and primary biliary cirrhosis\[[@B8]\].

In addition, improved results on the molecular mechanisms associated with the pathogenesis of hepatic fibrosis has led to growing acceptance of liver fibrosis as a potentially reversible process\[[@B9],[@B10]\]. Hepatic stellate cells (HSCs) are a worldwide research focus based on their activation and transdifferentiation to myofibroblasts, which ultimately results in liver fibrosis in response to a variety of injuries; more interestingly, previous studies have indicated that macrophages can influence the process of liver fibrosis *via* different mechanisms\[[@B11],[@B12]\]. Circulating macrophages arise from monocytes in the bone marrow (BM)\[[@B13]\], and Swirski et al\[[@B14]\] and other researchers\[[@B15],[@B16]\] have indicated that numerous monocytes in the spleen could be mobilized in the pathological state such that the spleen can be considered a monocyte reservoir. BM cell infusion can improve liver function\[[@B17]\] and decrease liver fibrosis\[[@B18]\], while splenectomy can result in liver function improvements for patients with liver cirrhosis\[[@B19]-[@B21]\]. Furthermore, a previous study indicated that splenectomy attenuated murine liver fibrosis when accompanied by hypersplenism\[[@B22]\].

On the other hand, liver biopsy is traditionally regarded as the gold standard for staging fibrosis. Nevertheless, as an invasive procedure, liver biopsy is unwelcome in patients who need repeated examination to monitor fibrosis progression. Furthermore, liver biopsy is limited by serious complications\[[@B23],[@B24]\], sampling errors\[[@B25]\], and both inter-pathologist and intra-pathologist variability\[[@B26]\]. Shear wave elastography, a reliable, rapid and non-invasive technique, has been used to evaluate tissue stiffness for many years and is increasingly important in the diagnosis of liver fibrosis\[[@B27]-[@B29]\]. Furthermore, an acoustic radiation force impulse (ARFI) technique, elastography point quantification (ElastPQ)\[[@B30]\], has been developed to measure the tissue\[[@B31]-[@B34]\]. However, no data are available on the changes in fibrotic liver stiffness after splenectomy at different pathological stages using ElastPQ.

We took advantage of a CCl~4~-induced liver fibrosis model in rabbits, from which liver biopsies were obtained at scheduled time points and ElastPQ was easily performed, to evaluate the correlation between liver fibrosis histological staging and liver stiffness measured by ElastPQ before splenectomy (Experiment 1). In addition, we determined the longitudinal changes in liver stiffness using ElastPQ after splenectomy at different pathological stages (Experiment 2).

MATERIALS AND METHODS
=====================

Animals
-------

One hundred and eight male New Zealand White rabbits weighing 2000-2500 g on arrival at the laboratory were purchased from the Experimental Animal Center of West China Medical Center, Sichuan University (Chengdu, China). All rabbits were acclimatized for one week to adapt to the new environment. Daily evaluation of rabbit health status was performed for one week to ensure the animals were clinically healthy prior to the experiments. The animals were individually housed in cages under a set temperature (22 ± 1 °C) and relative humidity (45% ± 10%) with a 12-h light/12-h dark cycle. Each animal was allowed free access to a standard diet for rabbits and fresh water. The experimental procedures were approved by the Institutional Animal Ethical Committee of Sichuan University (Chengdu, China), and all animals received humane care according to the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health (NIH Publication No. 85-23, revised 1996).

CCl~4~-induced liver fibrosis
-----------------------------

Liver fibrosis was induced by intraperitoneal injection of CCl~4~, as described previously\[[@B35]\]. Unfortunately, in a pilot experiment (10 rabbits), using the regimen reported by Zhang et al\[[@B35]\], a mortality rate of 60% (6 of 10 rabbits) was observed. The pilot study was stopped, and a modified method for induction of liver fibrosis was explored and eventually adopted. The injection started with 50% CCl~4~, which was diluted in olive oil, in doses of 0.10 mL/kg body weight twice per week for the first two weeks, which allowed the rabbits to gradually adapt to the toxic agent. Then, 50% CCl~4~ was given intraperitoneally in doses of 0.20 mL/kg body weight twice a week for another 18 wk in Experiment 1, and the liver injury induced by 50% CCl~4~ lasted for ten weeks from the first operation in Experiment 2. This method was sufficient to produce all stages of liver fibrosis. Humane endpoints were established in the modeling process according to the guidelines for assessing discomfort in experiment animals\[[@B36]\]. No animals died in Experiment 1.

Ultrasound-based examinations
-----------------------------

On the same day, just before surgery and blood collection, eight rabbits were chosen at random for preoperative examinations after at least four hours of fasting. The rabbits were anesthetized with a 40 mg/kg dose of pentobarbital *via* ear border vein injection and were then placed in the supine position with whole abdominal skin preparation. Liver stiffness measurements were then performed in or close to the subxiphoid region by two experienced examiners *via* ElastPQ with a 4-cm depth and a 0.5 cm × 1.5 cm region of interest on vessel-free areas at the end-inspiration phase with an iU22 ultrasound system (Royal Philips Electronics, the Netherlands) equipped with an ElastPQ feature and two transducers, C5-1 (1-5 MHz) (used in this study) and L9-3 (3-9 MHz) (not used in this study). Both examiners were blinded to the clinical, serological, and histological data. The results are expressed in kilopascals. ElastPQ results were obtained with 10 valid measurements from each operator; a success rate of at least 60% and an interquartile range of all successful measurements less than 30% of the median values were considered reliable. The successful measurements obtained by each operator were used for inter-examiner agreement analysis, while the median measurement obtained by both operators for each rabbit were used for other analyses in the current study.

Serum parameters
----------------

After ultrasound-based examinations, peripheral blood was collected *via* the ear border vein. Levels of the following parameters were determined: (1) class I biomarkers of liver fibrogenesis, including type IV collagen, and hyaluronic acid\[[@B37]\], were quantified using a standardized and optimized commercial radioimmunoassay kit (Haiyan Biotechnology Center, Shanghai, China) and (2) conventional liver function tests, including total bilirubin (TB), albumin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels (Leadman Biochemistry Co., Ltd, Beijing, China).

Surgical procedure
------------------

In Experiment 1, after 4-wk of modeling, the eight rabbits were randomly divided into two equal groups following preoperative examinations (ultrasound-based examinations and the blood test mentioned above). After disinfection, the operation began with a midline abdominal incision. In one group (Group S, splenectomy group), total splenectomy was performed by ligature of the splenic vascular pedicle with 4-0 chromic catgut; then, a 1-cm × 1-cm piece of hepatic tissue from the subxiphoid region of the liver was cut for biopsy. In another group (Group L, liver biopsy group or sham group), the same process was performed with the exception of total splenectomy. The abdominal cavity was closed after confirming that there was no active hemorrhage in all rabbits. To obtain different stages of liver fibrosis at different time intervals, the same surgical process was repeated for the remaining rabbits every two weeks until the 20^th^ wk. Due to humane endpoints and failed liver stiffness measurements, only seven rabbits underwent surgery at the 8^th^, 14^th^, 18^th^, and 20^th^ wk (Table [1](#T1){ref-type="table"}). In this case, four rabbits randomly underwent splenectomy plus liver biopsy, while the remaining three underwent liver biopsy alone.

###### 

Detailed information on the experimental process

  **Modeling time**   **Distribution of operation**   **Humane**   **Rabbits**   **POW 2**   **POW 4**   **POW 6**   **POW 8**   **POW 10**   **Humane**   **Exclusion**   **Death**   **Rabbits**
  ------------------- ------------------------------- ------------ ------------- ----------- ----------- ----------- ----------- ------------ ------------ --------------- ----------- -------------
  0W                  /                               0            90            /           /           /           /           /            /            /               /           /
  2W                  /                               0            90            /           /           /           /           /            /                            /           /
  4W                  AAAA                            0            82            AAAA        AAAA        AAA^5^      AA          AA           1            1               1           5
  BBBB                BBB                             BBB          BBB           BBB         BBB                                                                                       
  6W                  AAAA                            0            74            AAA         AAA         AAA         AA          AA           2            0               2           4
  BBBB                BBBB                            BBB          BBB           BB          BB                                                                                        
  8W                  AAAA                            2            64            AAA         AA          AA          AA          AA           2            0               1           4
  BBBB^5^             BBB                             BBB          BB            BB          BB                                                                                        
  10W                 AAAA                            3            53            AAA         AAA         AA          AA          AA           2            1               1           4
  BBBB                BBBB                            BBB          BBB^5^        BB          BB                                                                                        
  12W                 AAAA                            3            42            AAA         AAA         AA          AA          AA           3            0               1           4
  BBBB                BBB                             BB           BB            BB          BB                                                                                        
  14W                 AAAA                            2            32            AAA         AA          AA          AA          A            5            0               0           2
  BBBB^5^             BBB                             BBB          BB            B           B                                                                                         
  16W                 AAAA                            4            20            AAAA        AAA         AAA         AA          AA           4            0               1           3
  BBBB                BBB                             BB           BB            BB          B                                                                                         
  18W                 AAAA                            3            9             AAA         AAA         AAA         AA          AA           4            0               0           3
  BBBB^5^             BBB                             BB           BB            B           B                                                                                         
  20W                 AAAA                            2            0             AA          AA          AA          AA          A            4            1               0           2
  BBB                 BBB                             BBB          BB            BB^5^       B                                                                                         
  Total               68                              19           /             /           /           /           /           /            27           3               7           31

Number of rabbits with humane termination during Experiment 1;

Number of rabbits left excluding rabbits with humane termination and failed liver stiffness measurement *via* ElastPQ during Experiment 1;

Number of rabbits with humane termination during Experiment 2;

Number of rabbits left excluding rabbits with humane termination, failed liver stiffness measurement *via* ElastPQ, and death during Experiment 2; A^5^ and B^5^ indicate rabbits with failed LSM *via* ElastPQ. POW: Postoperative weeks; LSM: Liver stiffness measurement; ElastPQ: Elastography point quantification; A: Rabbits receiving splenectomy and liver biopsy; B: Rabbits receiving only liver biopsy.

In Experiment 2, after the first operation in each rabbit, a 1 cm × 1 cm piece of hepatic tissue was cut to dynamically monitor the changes in histological features according to the aforementioned ultrasound-based examinations and blood tests every two weeks for 10 wk. To avoid adhesions, chitosan (0.5 mL/surgery) was used. However, due to the increase in operation times, it was difficult to acquire liver tissue along the original midline incision. In this case, a left or right subcostal incision was needed. In Experiments 1 and 2, all animals were given penicillin intramuscularly at a dose of 40 U/rabbit to prevent infection during surgery, which was repeated once daily for a further two days. To reduce bias, only the hepatic tissue obtained in or very close to the subxiphoid region was included for analysis. In addition, due to humane endpoints and failed liver stiffness measurement (LSM) and death during the surgical procedure, only thirty-one rabbits with complete experimental data were available for analysis after the 10-wk surveillance period (Table [1](#T1){ref-type="table"}).

Liver histological assessment
-----------------------------

Liver biopsy samples taken at the time of the operation were fixed in formalin and embedded in paraffin. Sections (4 μm) were stained with hematoxylin and eosin and Masson trichrome. A biopsy sample with a minimum of 5 portal tracts was required for diagnosis. Two doctors with significant experience, who were blinded to all animal characteristics, were responsible for evaluating liver fibrosis, which was staged on a scale of 0-4 according to METAVIR\[[@B38]\] (F0, no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis and a few septa; F3, numerous septa without cirrhosis; and F4, cirrhosis). The fibrosis stage was independently assessed on each histological section by both doctors. In the case of discrepancies, histological sections were simultaneously reviewed again by the two doctors to reach a final consensus. Typical liver fibrosis stages (F1-F4) are illustrated in Figure [1](#F1){ref-type="fig"}.

![Masson trichrome staining for assessment of liver fibrosis stages according to METAVIR (A: F1, B: F2, C: F3, and D: F4; 100 ×) and the corresponding ElastPQ images (E: F1; F: F2; G: F3; and H: F4).](WJG-22-10166-g001){#F1}

Statistical analysis
--------------------

The quadratic-weighted k coefficient of Cohen was used to assess the consistency of the two doctors who were in charge of the pathological examinations, while the ICC (interclass correlation coefficient) was used to evaluate the agreement between the two examiners who performed the liver stiffness measurement *via* ElastPQ.

The median LSM obtained by both operators for each ElastPQ was calculated and used for further analyses. Because the LSM values were not normally distributed, the Kruskal-Wallis nonparametric analysis of variance test was used to compare these values with the categories of the consensus fibrosis stage. Correlations between the LSM and histologic fibrosis stage were further analyzed using Spearman correlation coefficients. The diagnostic performance of ElastPQ and serum fibrosis markers, including type IV collagen and hyaluronic acid, was assessed using receiver operating characteristic curves (ROC). The optimal cutoff values for predicting different fibrosis stages were chosen to maximize the sum of the sensitivity and specificity, and the corresponding positive predictive values (PPVs) and negative predictive values (NPVs) were computed. The AUC (area under ROC) values for the different diagnostic criteria for the same data were compared using the nonparametric DeLong test.

Quantitative data were presented as the mean ± SD or median (quartile), while categorical data were expressed as the number of cases with/without percentage. Statistical analyses also included the nonparametric Mann-Whitney *U* and Student's *t* tests.

All statistical analyses were performed using SPSS 19.0 (SPSS, Chicago, IL, United States) for Windows and significance was set at a *P* value \< 0.05.

RESULTS
=======

Experimental details
--------------------

The experimental details are presented in Table [1](#T1){ref-type="table"}. In addition to eight controls, ninety rabbits were planned for inclusion. As mentioned in the Materials and methods section due to humane termination (*n* = 19) and failed LSM (*n* = 3) during Experiment 1, information on sixty-eight rabbits was available for analysis. Similarly, 10 wk after splenectomy or sham operation, complete data for only thirty-one rabbits were available for comparable analyses.

Agreement between observers
---------------------------

The two doctors responsible for pathological diagnosis were initially in agreement for 197 (85.3%) of the 231 liver samples (231 = 76 + 5 × 31) (k coefficient = 0.792, *P* \< 0.01), and 100% agreement was reached after final reviews. The ElastPQ results identified by the two examiners were strongly correlated with an ICC value of 0.888, and are illustrated in Figure [2](#F2){ref-type="fig"}.

![Graph shows correlation of elastography point quantification results between two examiners (ICC value of 0.888, *r^2^* = 0.788, *P* \< 0.05).](WJG-22-10166-g002){#F2}

Basic characteristics of the included rabbits
---------------------------------------------

After 20 wk of medication, all fibrosis stages confirmed by pathological examinations were observed. As shown in Table [2](#T2){ref-type="table"}, F1 was diagnosed in 11 cases (14.5%), F2 in 16 (21.1%), F3 in 16 (21.1%), and F4 in 25 (32.9%), and eight healthy rabbits (F0, *n* = 8, 10.4%) were included as controls. Table [3](#T3){ref-type="table"} includes the basic information on rabbits with different stages of fibrosis. Except for body weight and TB, AST, ALT, and albumin levels, a trend for a stepwise increase in liver fibrosis progression was found in the parameters, including type IV collagen (F0: 200.8 ± 131.5 μg/L, F1: 427.1 ± 226.2 μg/L, F2: 683.4 ± 332.5 μg/L, F3: 1161.4 ± 482.5 μg/L, and F4: 1292.0 ± 689.7 μg/L), hyaluronic acid (F0: 225.6 ± 117.1 μg/L, F1: 475.7 ± 296.4 μg/L, F2: 676.2 ± 274.8 μg/L, F3: 724.0 ± 264.5 μg/L, and F4: 1182.3 ± 1091.3 μg/L), and LSM \[F0: 7.88 kPa (6.60-8.46 kPa), F1: 8.46 kPa (6.22-10.35 kPa), F2: 10.89 kPa (8.09-14.46 kPa), F3: 18.62 kPa (16.03-21.16 kPa), and F4: 25.10 kPa (20.28-30.95 kPa)\].

###### 

Distribution of liver fibrosis stages at different time intervals in Experiment 1

          **F0**   **F1**   **F2**   **F3**   **F4**
  ------- -------- -------- -------- -------- --------
  0 wk    98       /        /        /        /
  2 wk             /        /        /        /
  4 wk             5        3        0        0
  6 wk             3        4        1        0
  8 wk             2        4        1        0
  10 wk            1        2        3        2
  12 wk            0        2        1        5
  14 wk            0        1        2        4
  16 wk            0        0        4        4
  18 wk            0        0        3        4
  20 wk            0        0        1        6
  Total   8        11       16       16       25

###### 

Basic characteristics of rabbits with different liver fibrosis stages in Experiment 1

  **Parameters**            **F0 (*n* = 8)**   **F1 (*n* = 11)**   **F2 (*n* = 16)**    **F3 (*n* = 16)**     **F4 (*n* = 25)**
  ------------------------- ------------------ ------------------- -------------------- --------------------- ---------------------
  Body weight (kg)          2.34 ± 0.24        2.28 ± 0.27         2.39 ± 0.14          2.30 ± 0.38           2.24 ± 0.33
  Type IV collagen (μg/L)   200.8 ± 131.5      427.1 ± 226.2       683.4 ± 332.5        1161.4 ± 482.5        1292.0 ± 689.7
  Hyaluronic acid (μg/L)    225.6 ± 117.1      475.7 ± 296.4       676.2 ± 274.8        724.0 ± 264.5         1182.3 ± 1091.3
  TB (μmol/L)               0.98 ± 0.53        1.91 ± 0.63         2.20 ± 0.85          1.81 ± 0.82           1.64 ± 0.91
  AST (IU/L)                26.8 ± 14.7        345.0 ± 295.9       449.2 ± 304.7        666.4 ± 428.3         616.1 ± 609.2
  ALT (IU/L)                14.0 ± 3.7         254.7 ± 194.0       301.5 ± 210.7        456.3 ± 316.0         486.5 ± 295.8
  Albumin (g/L)             42.7 ± 4.9         40.4 ± 4.6          36.5 ± 4.3           32.3 ± 6.4            35.3 ± 5.9
  LSM (kPa)                 7.88 (6.60-8.46)   8.46 (6.22-10.35)   10.89 (8.09-14.46)   18.62 (16.03-21.16)   25.10 (20.28-30.95)

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; LSM: Liver stiffness measurement; TB: Total bilirubin.

Relationship between histological findings and LSM by ElastPQ
-------------------------------------------------------------

The median liver stiffness measured with ElastPQ in the eight controls was 7.88 kPa (6.60-8.46 kPa). The liver stiffness measured in the rabbits with fibrosis ranged from 5.86 kPa to 39.12 kPa. Based on the different fibrosis stages, the median liver stiffness values in the animals with F1 to F4 were 8.46 kPa (6.22-10.35 kPa), 10.89 kPa (8.09-14.46 kPa), 18.62 kPa (16.03-21.16 kPa), and 25.10 kPa (20.28-30.95 kPa), respectively, indicating a gradual increase in fibrosis progression, which is shown in Figure [3](#F3){ref-type="fig"}, with a Spearman correlation coefficient of 0.85 (*P* \< 0.001). Given that the distributions of ElastPQ results for F0 and F1 were comparable and only eight F0 rabbits were included, F0 and F1 rabbits were combined as a single group for further analyses. Significant differences in the LSM by ElastPQ between each fibrosis stage were observed (F0-1 *vs* F2, *P \<* 0.01; F2 *vs* F3, *P \<* 0.01; and F3 *vs* F4, *P \<* 0.01).

![Boxplot shows the elastography point quantification results for each fibrosis stage. The top and bottom of the boxes are the first and third quartiles, respectively. Accordingly, the length of the box plot represents the interquartile range within which 50% of the values were located. The lines through the middle of the boxes indicate the median values. ElastPQ: Elastography point quantification.](WJG-22-10166-g003){#F3}

Relationship between the LSM by ElastPQ and fibrosis blood tests
----------------------------------------------------------------

ROC curves of ElastPQ, hyaluronic acid, and type IV collagen for predicting minimal fibrosis (F0-F1 *vs* F2-F4), moderate fibrosis (F0-F2 *vs* F3-F4), and cirrhosis (F0-F3 *vs* F4) are shown in Figure [4A](#F4){ref-type="fig"}-C. The AUROC (area under ROC) of ElastPQ for predicting minimal fibrosis (0.931, 95%CI: 0.849-0.977) was comparable to those of hyaluronic acid (0.807, 95%CI: 0.700-0.889) and type IV collagen (0.919, 95%CI: 0.833-0.969), while the ElastPQ for predicting moderate fibrosis and cirrhosis (0.969, 95%CI: 0.901-0.995; 0.925, 95%CI: 0.841-0.973) was significantly superior to hyaluronic acid (0.677, 95%CI: 0.560-0.780; 0.670, 95%CI: 0.553-0.774) and type IV collagen (0.861, 95%CI: 0.762-0.930; 0.695, 95%CI: 0.578-0.795), which is summarized in Table [4](#T4){ref-type="table"}. The ElastPQ critical values for differentiating fibrosis stages were subsequently confirmed by the ROC, and the corresponding specificities, sensitivities, PPVs, and NPVs are listed in Table [5](#T5){ref-type="table"}.

###### 

Comparison between elastography point quantification and fibrosis blood tests

  **AUROC**          **F0-F1 *vs* F2-F4**   **F0-F2 *vs* F3-F4**                                  **F0-F3 *vs* F4**
  ------------------ ---------------------- ----------------------------------------------------- -----------------------------------------------------
  ElastPQ            0.931 (0.849-0.977)    0.969 (0.901-0.995)                                   0.925 (0.841-0.973)
  Hyaluronic acid    0.807 (0.700-0.889)    0.677 (0.560-0.780)[a](#T4FN1){ref-type="table-fn"}   0.670 (0.553-0.774)[a](#T4FN1){ref-type="table-fn"}
  Type IV collagen   0.919 (0.833-0.969)    0.861 (0.762-0.930)[a](#T4FN1){ref-type="table-fn"}   0.695 (0.578-0.795)[a](#T4FN1){ref-type="table-fn"}

Comparison of AUROC between ElastPQ and hyaluronic acid or type IV collagen,

*P* \< 0.05. ElastPQ: Elastography point quantification.

![Receiver operating characteristic curves of elastography point quantification and serum fibrosis markers for diagnosis of (A) minimal fibrosis (F0-F1 *vs* F2-F4), (B) moderate fibrosis (F0-F2 *vs* F3-F4), and (C) cirrhosis (F0-F3 *vs* F4). ElastPQ: Elastography point quantification.](WJG-22-10166-g004){#F4}

###### 

Cutoff and performance values of elastography point quantification for diagnosis of liver fibrosis stages

  **Parameter**          **F0-F1 *vs* F2-F4**   **F0-F2 *vs* F3-F4**   **F0-F3 *vs* F4**
  ---------------------- ---------------------- ---------------------- ---------------------
  AUROC                  0.931 (0.849-0.977)    0.969 (0.901-0.995)    0.925 (0.841-0.973)
  Optimal cutoff value   11.27                  14.89                  18.21
  Sensitivity (%)        82.5 (70.1-91.3)       87.8 (73.8-95.9)       88.0 (68.8-97.5)
  Specificity (%)        94.7 (74.0-99.9)       94.3 (80.8-99.3)       84.3 (71.4-93.0)
  PPV (%)                97.9 (88.9-99.9)       94.7 (82.3-99.4)       73.3 (54.1-87.7)
  NPV (%)                64.3 (44.1-81.4)       86.8 (71.9-95.6)       93.5 (82.1-98.6)

PPV: Positive predictive values; NPV: Negative predictive value.

Longitudinal change in the LSM by ElastPQ and liver function following splenectomy
----------------------------------------------------------------------------------

The longitudinal ElastPQ and laboratory data for rabbits with different stages of fibrosis after splenectomy and sham operation in Experiment 2 are shown in Tables [6](#T6){ref-type="table"} and [7](#T7){ref-type="table"}. For the nine rabbits with F1 liver fibrosis (five in the splenectomy group *vs* four in the sham group), the increase in ElastPQ values was delayed in the splenectomy group compared with that in the sham group during the following the operations (Figure [5A](#F5){ref-type="fig"}), while the changes in other laboratory parameters, including AST, ALT, albumin, and TB levels, indicated otherwise (Figure [6](#F6){ref-type="fig"}, Table [7](#T7){ref-type="table"}). For the rabbits with F2, F3, and F4 liver fibrosis, no favorable change in parameters, including the ElastPQ, AST, ALT, albumin, and TB levels, was detected in the splenectomy group compared with the sham group over the 10-wk period after the operations (Figure [5B](#F5){ref-type="fig"}-D, Figure [6](#F6){ref-type="fig"} and Table [7](#T7){ref-type="table"}).

![Dynamic changes in liver stiffness measurement by elastography point quantification after surgery in rabbits with F1 (A), F2 (B), F3 (C), and F4 (D) liver fibrosis (sham group *vs* splenectomy group). LSM: Liver stiffness measurement; ElastPQ: Elastography point quantification.](WJG-22-10166-g005){#F5}

###### 

Longitudinal changes in liver stiffness measurement (kPa) *via* elastography point quantification between splenectomy and sham groups

                                            **POW 0**             **POW 2**             **POW 4**             **POW 6**             **POW 8**             **POW 10**
  ------------------- --------------------- --------------------- --------------------- --------------------- --------------------- --------------------- ---------------------
  F1                  Group S (*n* = 5)     8.46 (6.63-8.50)      8.74 (6.97-8.91)      11.34 (9.13-12.89)    14.32 (11.45-15.45)   18.89 (16.43-19.23)   19.24 (17.78-21.09)
  Group L (*n* = 4)   8.59 (7.12-10.13)     12.79 (11.01-14.62)   14.35 (12.24-16.70)   16.30 (13.25-20.07)   21.01 (16.11-25.45)   23.34 (20.66-26.15)   
  F2                  Group S (*n* = 4)     10.81 (8.34-13.48)    14.45 (12.53-15.70)   18.28 (16.72-18.56)   20.73 (18.09-22.26)   25.50 (23.10-25.89)   30.79 (27.29-33.31)
  Group L (*n* = 4)   10.50 (9.31-11.96)    15.39 (13.55-16.92)   17.90 (16.01-19.27)   20.25 (18.92-21.51)   23.89 (23.15-25.24)   30.60 (28.54-32.29)   
  F3                  Group S (*n* = 4)     19.19 (17.77-21.25)   22.90 (20.70-25.17)   26.99 (25.13-28.88)   29.98 (26.14-33.23)   32.38 (29.06-35.89)   35.79 (33.79-37.31)
  Group L (*n* = 4)   22.08 (18.24-25.35)   25.17 (21.79-27.59)   27.21 (24.38-30.23)   29.72 (28.27-30.70)   31.89 (29.91-33.98)   32.22 (30.70-34.71)   
  F4                  Group S (*n* = 3)     27.56 (23.40-28.34)   31.23 (26.84-32.22)   30.12 (27.89-32.12)   36.12 (32.39-36.34)   35.10 (34.12-36.27)   36.12 (34.06-37.28)
  Group L (*n* = 3)   23.98 (20.21-28.66)   29.12 (23.68-31.19)   32.00 (28.17-33.00)   29.00 (28.56-32.56)   33.43 (33.32-35.32)   35.30 (35.25-37.21)   

POW: Postoperative weeks; Group S: Rabbits received splenectomy plus liver biopsy; Group L: Rabbits received liver biopsy only.

![Longitudinal changes in liver function following splenectomy *vs* sham operation at different liver fibrosis stages. A: Changes in AST for rabbits with F1-F4 liver fibrosis; B: Changes in ALT for rabbits with F1-F4 liver fibrosis; C: Changes in total bilirubin for rabbits with F1-F4 liver fibrosis; and D: Changes in albumin for rabbits with F1-F4 liver fibrosis. AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.](WJG-22-10166-g006){#F6}

###### 

Longitudinal changes in liver function between splenectomy and sham groups

                                          **POW 0**       **POW 2**       **POW 4**       **POW 6**       **POW 8**       **POW 10**
  ------------------- ------------------- --------------- --------------- --------------- --------------- --------------- ---------------
  AST (IU/L)                                                                                                              
  F1                  Group S (*n* = 5)   138.0 ± 87.3    236.7 ± 110.6   484.3 ± 244.2   307.3 ± 138.9   454.0 ± 291.3   574.3 ± 350.6
  Group L (*n* = 4)   447.0 ± 292.7       245.5 ± 98.3    589.5 ± 140.7   455.0 ± 309.7   517.5 ± 55.9    470.0 ± 155.6   
  F2                  Group S (*n* = 4)   353.6 ± 208.4   473.4 ± 212.1   426.0 ± 186.4   448.6 ± 286.4   658.2 ± 221.9   575.6 ± 104.4
  Group L (*n* = 4)   392.0 ± 290.5       493.5 ± 269.0   407.5 ± 100.4   506.3 ± 156.8   494.5 ± 88.8    550.0 ± 125.6   
  F3                  Group S (*n* = 4)   578.3 ± 219.5   681.3 ± 208.9   534.0 ± 292.2   622.7 ± 286.2   584.7 ± 144.5   713.3 ± 122.8
  Group L (*n* = 4)   598.8 ± 219.5       569.8 ± 208.9   651.5 ± 292.2   513.0 ± 286.2   435.5 ± 144.5   831.8 ± 122.8   
  F4                  Group S (*n* = 3)   562.2 ± 356.6   604.2 ± 314.3   578.4 ± 247.7   623.8 ± 101.1   672.6 ± 122.6   525.6 ± 153.2
  Group L (*n* = 3)   412.6 ± 190.9       508.7 ± 253.8   604.0 ± 121.8   616.7 ± 203.1   571.0 ± 145.7   480.3 ± 91.4    
  ALT (IU/L)                                                                                                              
  F1                  Group S (*n* = 5)   88.7 ± 39.2     270.3 ± 144.9   460.7 ± 227.5   379.0 ± 179.2   526.7 ± 185.8   440.7 ± 220.4
  Group L (*n* = 4)   195.0 ± 39.6        322.0 ± 76.4    430.5 ± 2.1     445.0 ± 108.9   560.5 ± 87.0    372.0 ± 198.0   
  F2                  Group S (*n* = 4)   224.6 ± 187.8   240.8 ± 96.7    355.8 ± 165.8   342.6 ± 165.1   436.8 ± 74.9    458.0 ± 92.4
  Group L (*n* = 4)   291.8 ± 65.9        364.3 ± 86.5    310.3 ± 35.8    414.5 ± 136.8   473.3 ± 140.5   498.3 ± 174.0   
  F3                  Group S (*n* = 4)   315.7 ± 232.7   434.0 ± 171.8   528.3 ± 137.7   588.0 ± 61.6    461.3 ± 208.2   497.3 ± 73.6
  Group L (*n* = 4)   477.8 ± 151.7       484.0 ± 34.4    459.3 ± 132.5   601.0 ± 274.9   488.8 ± 210.2   507.0 ± 133.2   
  F4                  Group S (*n* = 3)   416.8 ± 286.2   490.6 ± 43.3    626.2 ± 93.0    478.0 ± 83.3    550.6 ± 252.5   519.2 ± 44.9
  Group L (*n* = 3)   529.0 ± 167.0       475.8 ± 106.7   600.4 ± 116.3   512.6 ± 207.8   576.8 ± 233.1   695.4 ± 150.6   
  Albumin (g/L)                                                                                                           
  F1                  Group S (*n* = 5)   41.6 ± 2.4      40.5 ± 1.8      39.4 ± 2.3      40.5 ± 3.4      40.0 ± 2.0      39.8 ± 1.7
  Group L (*n* = 4)   41.3 ± 4.9          40.2 ± 3.0      40.3 ± 1.8      39.3 ± 0.6      39.3 ± 2.0      40.7 ± 1.3      
  F2                  Group S (*n* = 4)   39.0 ± 1.9      38.3 ± 1.9      38.3 ± 1.5      38.9 ± 2.0      38.9 ± 1.6      38.9 ± 0.8
  Group L (*n* = 4)   39.6 ± 1.6          39.6 ± 1.7      38.0 ± 1.5      39.5 ± 0.8      39.0 ± 1.4      38.9 ± 1.9      
  F3                  Group S (*n* = 4)   30.7 ± 4.3      30.3 ± 3.9      29.8 ± 3.3      31.0 ± 3.0      30.2 ± 3.8      30.5 ± 4.1
  Group L (*n* = 4)   31.1 ± 5.7          30.8 ± 5.1      31.8 ± 4.6      30.6 ± 5.2      30.9 ± 4.9      30.3 ± 4.2      
  F4                  Group S (*n* = 3)   35.8 ± 5.6      36.0 ± 4.7      34.5 ± 4.1      34.2 ± 4.8      35.1 ± 5.1      35.5 ± 3.6
  Group L (*n* = 3)   35.3 ± 6.6          34.9 ± 5.8      35.4 ± 6.1      34.8 ± 3.4      34.8 ± 4.9      35.0 ± 5.6      
  TB (μmol/L)                                                                                                             
  F1                  Group S (*n* = 5)   1.08 ± 0.10     1.30 ± 0.16     1.60 ± 0.16     1.58 ± 0.18     1.71 ± 0.23     1.70 ± 0.22
  Group L (*n* = 4)   1.34 ± 0.16         1.38 ± 0.08     1.39 ± 0.08     1.65 ± 0.20     1.51 ± 0.19     1.58 ± 0.25     
  F2                  Group S (*n* = 4)   2.01 ± 0.72     2.35 ± 0.58     2.45 ± 0.61     2.65 ± 0.47     2.76 ± 0.51     2.81 ± 0.54
  Group L (*n* = 4)   2.08 ± 0.23         2.45 ± 0.51     2.62 ± 0.45     2.67 ± 0.23     2.99 ± 0.15     2.68 ± 0.40     
  F3                  Group S (*n* = 4)   2.36 ± 0.64     2.52 ± 0.64     2.62 ± 0.51     2.66 ± 0.29     2.97 ± 0.19     3.09 ± 0.10
  Group L (*n* = 4)   2.59 ± 0.76         2.87 ± 0.42     2.88 ± 0.48     2.94 ± 0.33     3.13 ± 0.20     3.09 ± 0.12     
  F4                  Group S (*n* = 3)   2.30 ± 0.56     2.58 ± 0.54     2.73 ± 0.22     2.88 ± 0.18     3.05 ± 0.26     3.03 ± 0.38
  Group L (*n* = 3)   2.35 ± 0.84         2.49 ± 0.52     2.82 ± 0.67     2.96 ± 0.13     3.11 ± 0.48     3.08 ± 0.51     

POW: Postoperative weeks; Group S: Rabbits received splenectomy plus liver biopsy; Group L: Rabbits received liver biopsy only.

DISCUSSION
==========

In the current study, after four to twenty weeks of fibrosis induction, the LSM increased from 7.88 kPa to 5.86-39.12 kPa in all rabbits with different proven fibrosis stages. Two specific serum markers of liver fibrogenesis (type IV collagen and hyaluronic acid) were selected to reflect the progression of CCl~4~-induced liver fibrosis, and both markers showed a step-wise correlation with liver fibrosis stages compared to the LSM *via* ElastPQ, reinforcing that ElastPQ can reflect the severity of liver fibrosis. However, a comparison of the baseline values of liver stiffness in different studies cannot be performed mainly due to variations in the modeling methods and species.

Although there was a significant increase in the LSM *via* ElastPQ with increased fibrosis stage, there was a degree of overlap between consecutive stages. In this study, for F0-F2 liver fibrosis categories, the LSM was 7.88 (6.60-8.46), 8.46 (6.22-10.35), and 10.89 (8.09-14.46), respectively, which may have been due to an insufficient number of animals with F0-F2. A similar concern was reported in a previous study on the ARFI for assessing liver fibrosis\[[@B39]\]. The ElastPQ cutoff values for minimal fibrosis (F0-F1 *vs* F2-F4), moderate fibrosis (F0-F2 *vs* F3-F4), and cirrhosis (F0-F3 *vs* F4) were defined. As shown in Table [5](#T5){ref-type="table"}, the ElastPQ cutoff values for predicting different stages of fibrosis can be clearly distinguished, which may be due to the relatively uniform distribution of rabbits with different stages.

The areas under the ROC curves were compared for ElastPQ, hyaluronic acid and type IV collagen. The ElastPQ prediction of minimal fibrosis was comparable to that for hyaluronic acid and type IV collagen, while the ElastPQ prediction of moderate fibrosis and cirrhosis was significantly superior to hyaluronic acid. This outcome demonstrates that this non-invasive technique could have clinical utility.

With continuing basic research, the concept of liver fibrosis has changed from static and progressive to dynamic and bidirectional, especially when the causes of liver damage have been removed. In addition, because there is a significant correlation between the ElastPQ values and liver fibrosis stages, it is theoretically possible to use ElastPQ to non-invasively assess the effect of anti-fibrosis treatments. Indeed, previous studies have reported on the clinical application of TE for dynamically monitoring fibrosis regression during antiviral treatment in chronic hepatitis B and C patients, indicating that the TE values seem to decrease during antiviral therapy\[[@B40],[@B41]\].

Although splenectomy is performed for patients with hypersplenism in some institutions\[[@B21],[@B42]\], hypersplenism in most patients should be considered a laboratory abnormality that does not require treatment or further consideration\[[@B43]\]. However, a previous well-designed study indicated that splenectomy attenuated murine liver fibrosis\[[@B22]\]. Therefore, splenectomy remains controversial for patients with hypersplenism. In the present study, splenectomy was only used to group rabbits and then determine whether splenectomy at different liver fibrosis stages will delay or reverse the progression of liver fibrosis. A previous study indicated that the spleen plays an important regulatory role in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet\[[@B44]\]. In this study, a trend suggesting that splenectomy can delay the progression of early liver fibrosis (especially F1) was detected. A previous study using a rat liver fibrosis model indicated that spleen-derived TGF-β1 is involved in the development of liver fibrosis such that decreasing the TGF-β1 level by splenectomy could inhibit hepatic stellate cell activation and then improve liver fibrosis\[[@B45]\]. However, in the present study, splenectomy did not seem to improve late liver fibrosis (especially types F3 and F4); therefore, there may be another potential mechanism for improving early liver fibrosis following splenectomy.

Although activated HSCs have a great impact on liver fibrogenesis, recent studies have suggested that monocytes and their progeny macrophages are also responsible for liver fibrosis\[[@B46],[@B47]\]. Based on a study of monocytes derived from BM\[[@B13]\] as well as studies by Swirski et al\[[@B14]\] and other researchers\[[@B15],[@B16]\], there are numerous monocytes in the spleen that could be mobilized in pathological states. As a result, the spleen can be considered a monocyte reservoir. An interesting previous study demonstrated that the spleen is a site for storing and rapidly deploying monocytes involved in inflammation regulation\[[@B14]\]. Therefore, performing splenectomy in the early stages of liver fibrosis would block the rapid deployment of monocytes to the liver, which may alleviate the inflammatory reaction and delay liver fibrosis. In contrast, performing splenectomy in the late stage would not help to postpone liver fibrosis, which may be explained by the hypothesis that during the late stage, monocytes from BM play a predominant role in liver fibrosis. However, it should be further determined whether the diversity of monocyte origin influences the different stages of liver fibrosis.

In summary, ElastPQ is an available, convenient, objective and non-invasive technique for assessing liver stiffness in rabbits with CCl~4~-induced liver fibrosis, and paves the way for its clinical application. Additionally, liver stiffness measurements with ElastPQ can dynamically monitor the changes in liver stiffness in rabbit models, or patients, after splenectomy. However, the underlying mechanism by which early splenectomy can decelerate liver fibrosis should be further studied.

COMMENTS
========

Background
----------

Elastography point quantification (ElastPQ) is a non-invasive technique for assessing tissue stiffness and was used in this study. Splenectomy is a surgical intervention for liver cirrhosis patients with hypersplenism. However, no evidence of changes in fibrotic liver stiffness after splenectomy at different pathological stages using ElastPQ has previously been available.

Research frontiers
------------------

Liver biopsy is the reference standard for staging fibrosis. Nevertheless, because of its invasive nature, liver biopsy is difficult to perform in patients who require repeated examination to monitor liver fibrosis progression. An acoustic radiation force impulse (ARFI) technique, ElastPQ, has been developed for measuring tissue stiffness. In this study, the author used a liver fibrosis animal model to demonstrate that ElastPQ is an available, convenient, objective and non-invasive technique for assessing liver stiffness in rabbits with CCl~4~-induced liver fibrosis. In addition, the changes in liver stiffness in rabbit models, or patients, after splenectomy can be dynamically monitored by ElastPQ.

Innovations and breakthrough
----------------------------

This is the first animal experiment to confirm that liver stiffness measurements with ElastPQ could be used to dynamically monitor the changes in liver stiffness. The results provide good news for liver fibrosis patients who are in need of long-term follow-up.

Applications
------------

Based on this study, ElastPQ could dynamically monitor the changes in liver stiffness after interventions.

Terminology
-----------

ElastPQ is an ARFI technique that can non-invasively measure tissue stiffness.

Peer-review
-----------

This is a well-supported paper presenting a study on utilizing CCl~4~-induced liver fibrosis to evaluate liver stiffness measurement approaches.
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